Eli Lilly's oral GLP-1 orforglipron tops oral semaglutide in Phase 3 diabetes trial, filed in 40+ countries

 

• Detailed Phase 3 ACHIEVE-3 results for orforglipron in type 2 diabetes published in The Lancet.
• Oral GLP-1 orforglipron showed significantly greater A1C reduction and weight loss than oral semaglutide.
• Eli Lilly has submitted orforglipron to regulators in over 40 countries.
• Company expects potential U.S. obesity regulatory action on orforglipron in Q2 2026.

https://finviz.com/quote.ashx?t=LLY&p=d